Shezad Malik Law Firm Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Articles Tagged with Diabetes Drug

Onglyza Heart Failure. Wrendell Chester, from Texas, recently filed a personal injury and product liability lawsuit, against Bristol-Myers Squibb and AstraZeneca, the manufacturers of the drug.

Onglyza Heart Failure Attorney

Onglyza and Kombiglyze linked to heart failure according to the FDA Warning

Chester claims that the companies failed to adequately warn patients and doctors about the risk of heart failure from side effects of Onglyza and failed to conduct proper research and testing.

Takeda Pharmaceuticals has decided to wrap up the remaining Actos linked bladder cancer lawsuits. Takeda settled two more claims this week, after a two-month trial in Nevada state court.

Actos_Bladder_Cancer_AttorneyRecently, Takeda ear-marked $2.4 billion for settlements to settle thousands of personal injury and defective product liability lawsuits brought by diabetic patients who were diagnosed with bladder cancer after using Actos.

Actos Settlement Band Wagon Keeps On Rolling

In September, Takeda said that 96% of Actos claimants signed up for its $2.3 billion settlement offer, settling most of the 8,000 plus cases pending in state and federal courts.

On other fronts, Takeda settled the 7 out of 9 cases that had been tried and were up on appeal. Takeda also agreed to toss in an extra $100 million if 97% of claims matched up with settlement criteria. Takeda is trying close down the Actos bladder litigation, by encouraging as many plaintiffs as possible to settle their injury claims and keep the settlement band wagon rolling on.

Continue reading

There are several thousand lawsuits filed by folks both in state and federal courts by patients who took the prescription drug pioglitazone, sold as brand name Actos and later developed bladder cancer. Doctors prescribe Actos to treat patients with Type 2 Diabetes.

Actos_Bladder_Cancer_AttorneyTakeda Actos Bladder Cancer Verdict

On April 7, 2014, a federal jury in Louisiana found Takeda failed to adequately warn about bladder cancer risks of Actos. Jurors also found that executives of Takeda acted with wanton and reckless disregard for patient safety and awarded a total of $9 billion in punitive damages.

After a record breaking pharmaceutical $9 billion jury verdict involving Actos bladder cancer lawsuit, Takeda Pharmaceuticals and Eli Lilly, Actos manufacturers, have filed for a new trial. Takeda Pharmaceuticals and Eli Lilly, claim that the massive award shows that the jury acted with “passion and prejudice”.

Actos_Bladder_Cancer_AttorneyActos Record $9B Verdict

In April, a federal jury in Louisiana hammered Takeda with $1.5 million in compensatory damages and a whopping $9 billion in punitive damages. Terrance Allen and his wife’s claim, was the first out of several thousand Actos lawsuits in the federal court system to go to trial.


The jury in federal court in Louisiana, sent a loud and clear message on Monday, in rendering a bombshell verdict. Takeda Pharmaceutical Co. and Eli Lilly & Co.  were ordered to pay a combined $9 billion in punitive damages. The federal court jury found they hid the cancer risks of their Actos diabetes drug in the first federal U.S. trial.
https://www.youtube.com/watch?v=G4ItYan1QWo&feature=player_detailpage
Takeda, Lilly $9 Billion Punitive DamagesTakeda, based in Osaka, Japan, was ordered to pay $6 billion by the jury yesterday in Lafayette, Louisiana. Indianapolis-based Eli Lilly, Takeda’s partner, was ordered to pay $3 billion. Punitive damages are awarded in these types of cases to punish the companies for their wrongful acts.

After 33 grueling days of hotly contested trial testimony, the first federal Actos bladder cancer lawsuit trial has ended. The jury is scheduled to hear closing arguments on Monday and then deliberations will begin.

Federal Actos Trial: The Details

All Byetta, Januvia, Janumet and Victoza cancer lawsuits are consolidated and centralized as part of an MDL, or Multidistrict Litigation.

These product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.”

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has agreed to consolidate all Byetta, Januvia, Janumet and Victoza cancer lawsuits, centralizing the litigation as part of an MDL, or Multidistrict Litigation. The JPML issued a Transfer Order on August 26, and these product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.”

Januvia Pancreatic Cancer AttorneyThe product liability cases will be centralized before U.S. District Judge Battaglia in the Southern District of California for coordinated handling during pretrial proceedings. The consolidation is beneficial for all parties in complex pharmaceutical litigation, to reduce repetative discovery and to prevent conflicting rulings from different federal judges.

What are Incretin Mimetics?

According to the FDA, there is no scientific evidence to confirm that a group of type 2 diabetes drugs called GLP-1 inhibitors is linked to pancreatic cancer. The FDA decision comes on the heels of the European Medicines Agency, which stated that they have been unable to confirm an increased risk of pancreatic cancer linked to side effects of Byetta, Januvia, Janumet, Victoza and other incretin mimetic drugs.

Januvia Pancreatic Cancer AttorneyThe FDA has apparently completed its safety review into the new group of medications, known as incretin mimetics, and is preparing to report that it has found no conclusive connection between the medications and pancreatic cancer. According to the EMA, its experts reviewed the data and found “methodological limitations and potential sources of bias” and decided the available data don’t bear out worries about an increased risk of “pancreatic adverse events.”

The report addresses the entire group of incretin mimetics, which comprises GLP-1 agonists, which mimic a key hormone, and DPP-4 inhibitors, which interfere with a protein that breaks down the same hormone.

Contact Information